Patents by Inventor Ramesh Bhatt

Ramesh Bhatt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitory T cell receptor peptides and discovery methods
    Patent number: 12606816
    Abstract: Disclosed herein are methods of inhibiting an interaction of a T cell receptor with a peptide-major histocompatibility complex comprising administering inhibitory peptides that bind to the T cell receptor without the aid of a major histocompatibility complex to inhibit the interaction, and methods of identifying the inhibitory peptides.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: April 21, 2026
    Assignee: JANUX THERAPEUTICS, INC.
    Inventors: David Campbell, Ramesh Bhatt, Thomas Diraimondo
  • COMPOSITIONS AND METHODS RELATED TO TUMOR ACTIVATED ANTIBODIES TARGETING EGFR AND EFFECTOR CELL ANTIGENS
    Publication number: 20260014267
    Abstract: Provided herein are multispecific antibodies that selectively bind to EGFR and effector cell antigens such as CD3, pharmaceutical compositions thereof, as well as nucleic acids, and methods for making and discovering the same.
    Type: Application
    Filed: September 12, 2025
    Publication date: January 15, 2026
    Inventors: David CAMPBELL, Thomas R. DIRAIMONDO, Ramesh BHATT
  • Compositions and methods related to tumor activated antibodies targeting EGFR and effector cell antigens
    Patent number: 12433953
    Abstract: Provided herein are multispecific antibodies that selectively bind to EGFR and effector cell antigens such as CD3, pharmaceutical compositions thereof, as well as nucleic acids, and methods for making and discovering the same.
    Type: Grant
    Filed: October 17, 2024
    Date of Patent: October 7, 2025
    Assignee: JANUX THERAPEUTICS, INC.
    Inventors: David Campbell, Thomas R. Diraimondo, Ramesh Bhatt
  • ANG-2/VEGF ANTIBODIES AND USES THEREOF
    Publication number: 20250250330
    Abstract: Described herein are antibodies that bind VEGF_A or ANG-2, or bispecific antibodies that bind VEGF_A and ANG-2. Antibodies of this disclosure are useful for treating diseases of the eye including macular degeneration.
    Type: Application
    Filed: January 8, 2025
    Publication date: August 7, 2025
    Inventors: Ramanath BHANDARI, Li XU, Ramesh BHATT, Ram Prashanth PALANKI
  • COMPOSITIONS AND METHODS RELATED TO TUMOR ACTIVATED ANTIBODIES TARGETING EGFR AND EFFECTOR CELL ANTIGENS
    Publication number: 20250177552
    Abstract: Provided herein are multispecific antibodies that selectively bind to EGFR and effector cell antigens such as CD3, pharmaceutical compositions thereof, as well as nucleic acids, and methods for making and discovering the same.
    Type: Application
    Filed: October 17, 2024
    Publication date: June 5, 2025
    Inventors: David CAMPBELL, Thomas R. DIRAIMONDO, Ramesh BHATT
  • Compositions and methods related to tumor activated antibodies targeting EGFR and effector cell antigens
    Patent number: 12161724
    Abstract: Provided herein are multispecific antibodies for redirecting T cells to cancers, that rely on binding of one antigen interacting portion of the antibody to a tumor-associated antigen or marker, such as epidermal growth factor receptor (EGFR), while a second antigen interacting portion can bind to an effector cell antigen on a T cell, such as CD3, pharmaceutical compositions thereof, as well as nucleic acids, and methods for making and discovering the same.
    Type: Grant
    Filed: May 4, 2022
    Date of Patent: December 10, 2024
    Assignee: JANUX THERAPEUTICS, INC.
    Inventors: David Campbell, Thomas R. Diraimondo, Ramesh Bhatt
  • COMPOSITIONS AND METHODS RELATING TO TUMOR ACTIVATED T CELL ENGAGERS
    Publication number: 20240376226
    Abstract: Provided herein are modified T cell engagers, pharmaceutical compositions thereof, as well as nucleic acids, and methods for making and discovering the same. The modified T cell engagers described herein are modified with a peptide and a half-life extending molecule.
    Type: Application
    Filed: July 26, 2024
    Publication date: November 14, 2024
    Inventors: David CAMPBELL, Ramesh BHATT, Thomas R. DIRAIMONDO
  • COMPOSITIONS AND METHODS RELATED TO TUMOR ACTIVATED ANTIBODIES TARGETING EGFR AND EFFECTOR CELL ANTIGENS
    Publication number: 20240252669
    Abstract: Provided herein are multispecific antibodies for redirecting T cells to cancers, that rely on binding of one antigen interacting portion of the antibody to a tumor-associated antigen or marker, such as epidermal growth factor receptor (EGFR), while a second antigen interacting portion can bind to an effector cell antigen on a T cell, such as CD3, pharmaceutical compositions thereof, as well as nucleic acids, and methods for making and discovering the same.
    Type: Application
    Filed: May 4, 2022
    Publication date: August 1, 2024
    Inventors: David CAMPBELL, Thomas R. DIRAIMONDO, Ramesh BHATT
  • ANTIBODIES TARGETING EGFR AND CD3 AND USES THEREOF
    Publication number: 20240254241
    Abstract: Provided herein are antibodies that selectively bind to EGFR and CD3, pharmaceutical compositions thereof, as well as methods of producing such antibodies.
    Type: Application
    Filed: May 10, 2022
    Publication date: August 1, 2024
    Inventors: David CAMPBELL, Thomas R. DIRAIMONDO, Ramesh BHATT
  • HALF-LIFE EXTENDING COMPOSITIONS AND METHODS
    Publication number: 20240034814
    Abstract: Disclosed herein are polypeptides and polypeptides complexes comprising a half-life extending antibody or antibody fragment. In some embodiments, the half-life extending antibody or antibody fragment is a single domain antibody.
    Type: Application
    Filed: December 7, 2021
    Publication date: February 1, 2024
    Inventors: David CAMPBELL, Thomas R. DIRAIMONDO, Ramesh BHATT
  • MODIFIED ANTIBODIES
    Publication number: 20230270854
    Abstract: Provided herein are modified antibodies, pharmaceutical compositions thereof, as well as nucleic acids, and methods for making and discovering the same. The modified antibodies described herein are modified with a peptide. The peptide binds at or near the antigen binding site of the antibody at physiological pH, thus reducing binding affinity of the antibody for a target antigen. At acidic pH, the binding interaction of the peptide at or near the antigen binding site is disrupted, thus enabling binding with a target antigen.
    Type: Application
    Filed: December 8, 2022
    Publication date: August 31, 2023
    Inventors: David Campbell, Ramesh Bhatt, William J. Dower, Steven E. Cwirla, Blake M. Williams
  • COMPOSITIONS AND METHODS RELATING TO TUMOR ACTIVATED T CELL ENGAGERS
    Publication number: 20230220109
    Abstract: Provided herein are modified T cell engagers, pharmaceutical compositions thereof, as well as nucleic acids, and methods for making and discovering the same. The modified T cell engagers described herein are modified with a peptide and a half-life extending molecule.
    Type: Application
    Filed: June 5, 2020
    Publication date: July 13, 2023
    Inventors: David CAMPBELL, Ramesh BHATT, Thomas R. DIRAIMONDO
  • TUMOR ACTIVATED T CELL ENGAGERS AND METHODS OF USE THEREOF
    Publication number: 20230220105
    Abstract: Provided herein are modified T cell engagers, pharmaceutical compositions thereof, as well as nucleic acids, and methods for making and discovering the same. The modified T cell engagers described herein are modified with a peptide and a half-life extending molecule.
    Type: Application
    Filed: June 5, 2020
    Publication date: July 13, 2023
    Inventors: David CAMPBELL, Ramesh BHATT, Thomas R. DIRAIMONDO
  • ACVR2A-SPECIFIC ANTIBODY AND METHOD OF USE THEREOF
    Publication number: 20210380703
    Abstract: The present disclosure provides antibodies that specifically bind to and block signaling by ACVR2A, i.e., ACVR2A but not ACVR2B, as well as methods for using the same. The antibodies may be used for the treatment of a number of conditions associated with muscle atrophy, as well as other conditions.
    Type: Application
    Filed: August 4, 2021
    Publication date: December 9, 2021
    Inventors: Todd M. KINSELLA, Ramesh BHATT, Kristen BALTGALVIS
  • INHIBITORY T CELL RECEPTOR PEPTIDES AND DISCOVERY METHODS
    Publication number: 20210371849
    Abstract: Disclosed herein are methods of inhibiting an interaction of a T cell receptor with a peptide-major histocompatibility complex comprising administering inhibitory peptides that bind to the T cell receptor without the aid of a major histocompatibility complex to inhibit the interaction, and methods of identifying the inhibitory peptides.
    Type: Application
    Filed: July 31, 2019
    Publication date: December 2, 2021
    Inventors: David CAMPBELL, Ramesh BHATT, Thomas DIRAIMONDO
  • Method of using a bispecific antibody to conditionally inhibit a receptor signaling complex
    Patent number: 11111305
    Abstract: This invention describes the design of bispecific antibodies that function as conditionally effective therapeutics by binding to a functionally silent epitope on one component of a targeted signaling complex and simultaneously binding to a second protein, whose expression or accessibility is cell- or disease environment-specific, and whose antibody-driven proximity to the signaling complex leads to an alteration of signal transduction.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: September 7, 2021
    Assignee: TORCH THERAPEUTICS
    Inventors: Todd M. Kinsella, Donald G. Payan, Ramesh Bhatt, Kristen Baltgalvis
  • ACVR2A-specific antibody and method of treatment of muscle atrophy
    Patent number: 11104737
    Abstract: The present disclosure provides antibodies that specifically bind to and block signaling by ACVR2A, i.e., ACVR2A but not ACVR2B, as well as methods for using the same. The antibodies may be used for the treatment of a number of conditions associated with muscle atrophy, as well as other conditions.
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: August 31, 2021
    Assignee: RIGEL PHARMACEUTICALS, INC.
    Inventors: Todd M. Kinsella, Ramesh Bhatt, Kristen Baltgalvis
  • MODIFIED T CELL RECEPTORS
    Publication number: 20210115106
    Abstract: Provided herein are modified T cell receptors (TCRs), pharmaceutical compositions thereof, as well as nucleic acids, and methods for making and discovering the same. The modified TCRs described herein are modified with a peptide.
    Type: Application
    Filed: December 6, 2018
    Publication date: April 22, 2021
    Inventors: David CAMPBELL, Ramesh BHATT, Thomas R. DIRAIMONDO, Steven E. CWIRLA, Blake M. WILLIAMS, Praechompoo PONGTORNPIPAT, William J. DOWER
  • MODIFIED BISPECIFIC T CELL RECEPTORS
    Publication number: 20200385440
    Abstract: Provided herein are modified T cell receptors (TCRs), pharmaceutical compositions thereof, as well as nucleic acids, and methods for making and discovering the same. The modified TCRs described herein are modified with a peptide.
    Type: Application
    Filed: December 6, 2018
    Publication date: December 10, 2020
    Inventors: David CAMPBELL, Ramesh BHATT, Thomas R. DIRAIMONDO, Steven E. CWIRLA, Blake M. WILLIAMS, Praechompoo PONGTORNPIPAT, William J. DOWER
  • ACVR2A-SPECIFIC ANTIBODY AND METHOD OF USE THEREOF
    Publication number: 20190382496
    Abstract: The present disclosure provides antibodies that specifically bind to and block signaling by ACVR2A, i.e., ACVR2A but not ACVR2B, as well as methods for using the same. The antibodies may be used for the treatment of a number of conditions associated with muscle atrophy, as well as other conditions.
    Type: Application
    Filed: March 27, 2018
    Publication date: December 19, 2019
    Inventors: Todd M. KINSELLA, Ramesh BHATT, Kristen BALTGALVIS